Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × avelumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 6 Genitourinary 6 Thoracic 5 Gastrointestinal 3 Head & Neck 2 Gynecologic 2 Breast 2 Sarcoma 1 NET 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Neuroendocrine Tumors 4 Carcinoma, Neuroendocrine 3 Carcinoma, Merkel Cell 2 Neoplasms 1 Lymphoma, Follicular 1 Carcinoma 1

Interventions

Everolimus 6 Sunitinib 4 Octreotide 4 Leucovorin 4 dabrafenib 3 Fluorouracil 3 trametinib 2 selpercatinib 2 lutetium Lu 177 dotatate 2 alectinib 2 PM 01183 2 Oxaliplatin 2 Irinotecan 2 Fulvestrant 2 Doxorubicin 2 Cisplatin 2 3-Iodobenzylguanidine 2 tipifarnib 1 telotristat ethyl 1 somapacitan 1 ribociclib 1 repotrectinib 1 pralsetinib 1 pentetreotide 1 pasireotide 1 motesanib diphosphate 1 irinotecan sucrosofate 1 fostamatinib 1 epothilone B 1 entinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡